Mersana Therapeutics Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2016 | $33 M | No. 4 | $10 to $50 million | equity | SEC | |
| Feb 2015 | $10 M | No. 3 | $10 to $50 million | equity | SEC | |
| Sep 2013 | $15 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Jul 2012 | $13 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Mersana Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2016).
SEC Form D · Jun 2016
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2016
That is all the official record says: Mersana Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Nea 14 GP, LTD | Company | not stated | not stated | Held Series A-1, B-1 and C-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| NEA Partners 14, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B-1 and C-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Enterprise Associates 14, L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B-1 and C-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 13 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Anna Protopapas | Executive officer | Jun 2016 |
| Donald Bergstrom | Executive officer | Jun 2016 |
| Eva Jack | Executive officer | Jun 2016 |
| Michael J. Kaufman | Executive officer | Jun 2016 |
| Timothy Lowinger | Executive officer | Jun 2016 |
| Wayne J. Foster | Executive officer | Jun 2016 |
| David Mott | Executive officer | Mar 2015 |
| Peter Park | Executive officer | Mar 2015 |
| Wayne Foster | Executive officer | Mar 2015 |
| Timothy B. Lowinger | Executive officer | Apr 2014 |
| Wayne B. Foster | Executive officer | Apr 2014 |
| Michael G. Metzger | Executive officer | Oct 2013 |
| Nicholas G. Bacopoulos | Executive officer | Oct 2013 |
| Peter G. Park | Executive officer | Oct 2013 |
| Burkhard B. Blank | Executive officer | Aug 2012 |
| Anna Protopapas | Director | Jun 2016 |
| David Mott | Director | Jun 2016 |
| Elaine J. Jones | Director | Jun 2016 |
| Sara J. Nayeem | Director | Jun 2016 |
| Thomas J. Beck | Director | Jun 2016 |
| Elaine Jones | Director | Mar 2015 |
| Sara Nayeem | Director | Mar 2015 |
| Thomas Beck | Director | Mar 2015 |
| Nicholas G. Bacopoulos | Director | Apr 2014 |
| David G. Mott | Director | Oct 2013 |
| Sara G. Nayeem | Director | Oct 2013 |
| Thomas G. Beck | Director | Oct 2013 |
| Karen G. Hong | Director | Aug 2012 |
About
Company in Cambridge, United States.